AtriCure Reports First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG
May 2, 2024 5:25 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $58.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q1 revenue of $108.9M (+16.4% y/y rep, +16.3% y/y cc), above consensus of $106.9M. U.S. Q1 revenue was $90.2M (+15.4% y/y), slightly higher than consensus of $89.5M, and International revenue of $18.6M (+21.5% y/y rep, +21.1% y/y cc) beat consensus of $17.4M. The closely watched U.S. Appendage Management segment reported $35.9M (+11% y/y) in Q1 sales, missing consensus... More
